Lessee, Operating Lease, Liability, Undiscounted Excess Amount of LIGAND PHARMACEUTICALS INC from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
LIGAND PHARMACEUTICALS INC quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • LIGAND PHARMACEUTICALS INC Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Dec 2025 was $1,150,000, a 42% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

LIGAND PHARMACEUTICALS INC Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,150,000 -$833,000 -42% 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q4 2024 $1,983,000 -$255,000 -11% 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q4 2023 $2,238,000 -$2,142,000 -49% 31 Dec 2023 10-K 29 Feb 2024 2023 FY
Q4 2022 $4,380,000 +$355,000 +8.8% 31 Dec 2022 10-K 28 Feb 2023 2022 FY
Q3 2022 $10,494,000 +$7,630,000 +266% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $6,742,000 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $3,864,000 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $4,025,000 +$2,894,000 +256% 31 Dec 2021 10-K 28 Feb 2022 2021 FY
Q3 2021 $2,864,000 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q4 2020 $1,131,000 -$1,523,000 -57% 31 Dec 2020 10-K 24 Feb 2021 2020 FY
Q4 2019 $2,654,000 31 Dec 2019 10-K 27 Feb 2020 2019 FY
Q3 2019 $2,734,000 30 Sep 2019 10-Q 08 Nov 2019 2019 Q3
Q2 2019 $2,864,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $1,376,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.